Zealand Pharma announces amendments to its Articles of Association following the granting of warrants

Rhea-AI Summary

Zealand Pharma has announced amendments to its Articles of Association following the granting of employee warrants. The company aims to attract and retain top talent through this incentive scheme, aligning interests of management, employees, and shareholders. The related share capital increase has been officially registered with the Danish Business Authority. Zealand Pharma, based in Copenhagen, has a focus on innovative peptide-based medicines, with several drug candidates in clinical development and collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals.

Positive

• Warrant program to attract and retain top talent.
• Amendments registered with the Danish Business Authority indicate compliance.
• Multiple drug candidates in clinical development enhance growth potential.

Negative

• None.

Company announcement – No. 50 / 2020

Zealand Pharma announces amendments to its Articles of Association following the granting of warrants

Copenhagen, September 18, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that its Articles of Association have been amended to reflect the recent grant of warrants to employees, as announced in Company Announcement no. 49/2020 on September 14, 2020.

The warrant program is an incentive scheme reflecting Zealand’s objective to attract and retain first-rate employees and help ensure shared short- and long-term interests for the management, employees and shareholders of the Company.

The amendments to Zealand’s Articles of Association entailed by the share capital increase have been registered today with the Danish Business Authority.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go^®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.  

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Mads Kronborg
Head of Investor Relations & Communication
Phone: +45 5060 3707
Email: mkronborg@zealandpharma.com

For U.S. Media
David Rosen
Argot Partners
Phone: 212-600-1902
Email: media@zealandpharma.com

FAQ

What changes did Zealand Pharma announce on September 18, 2020?

On September 18, 2020, Zealand Pharma announced amendments to its Articles of Association due to the granting of employee warrants.

What is the purpose of the warrant program announced by Zealand Pharma?

The warrant program is designed to attract and retain high-quality employees, aligning their interests with those of management and shareholders.

How many drug candidates does Zealand Pharma have in clinical development?

Zealand Pharma has over 10 drug candidates that have advanced into clinical development.

What collaborations does Zealand Pharma have that enhance its market position?

Zealand Pharma collaborates with Boehringer Ingelheim and Alexion Pharmaceuticals, which could broaden patient access to its peptide therapeutics.